Jilin Province Huinan Changlong Bio-pharmacy Co (HKSE:08049) Total Payout Ratio: (As of Sep. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:08049 Jilin Province Huinan Changlong Bio-pharmacy Co Ltd HKSE:08049
78 GF Score
Price HK$2.31
GF Value HK$1.82
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is Jilin Province Huinan Changlong Bio-pharmacy Co Total Payout Ratio?

Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.

Jilin Province Huinan Changlong Bio-pharmacy Co's current Total Payout Ratio is .

Jilin Province Huinan Changlong Bio-pharmacy Co Total Payout Ratio Related Terms

Jilin Province Huinan Changlong Bio-pharmacy Co Total Payout Ratio Historical Data

* Premium members only.

The historical data trend for Jilin Province Huinan Changlong Bio-pharmacy Co's Total Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jilin Province Huinan Changlong Bio-pharmacy Co Total Payout Ratio Chart

Jilin Province Huinan Changlong Bio-pharmacy Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Payout Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Jilin Province Huinan Changlong Bio-pharmacy Co Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Total Payout Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

HKSE:08049 vs ZTS: Total Payout Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Jilin Province Huinan Changlong Bio-pharmacy Co's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Jilin Province Huinan Changlong Bio-pharmacy Co Total Payout Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Jilin Province Huinan Changlong Bio-pharmacy Co's Total Payout Ratio distribution charts can be found below:

* The bar in red indicates where Jilin Province Huinan Changlong Bio-pharmacy Co's Total Payout Ratio falls into.


HKSE:08049
78GF Score
Jilin Province Huinan Changlong Bio-pharmacy Co Ltd HKSE:08049
Total Payout Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jilin Province Huinan Changlong Bio-pharmacy Co Total Payout Ratio Calculation

Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.

Jilin Province Huinan Changlong Bio-pharmacy Co's Total Payout Ratio for the fiscal year that ended in Dec. 2025 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (-0 + 0 + -128.62230272096) / 215.6943460628
=0.60

Jilin Province Huinan Changlong Bio-pharmacy Co's Total Payout Ratio for the quarter that ended in Jun. 2026 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- ( + + ) / 140.03283032491
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Is Jilin Province Huinan Changlong Bio-pharmacy Co (HKSE:08049) Overvalued in 2026?

Based on GuruFocus' analysis, Jilin Province Huinan Changlong Bio-pharmacy Co stock appears to be overvalued. The current stock price of HK$2.31 is trading 26.9% above its estimated GF Value™ of HK$1.82. GuruFocus considers Jilin Province Huinan Changlong Bio-pharmacy Co to be Modestly Overvalued.

Key valuation signals for HKSE:08049:

  • Total Payout Ratio:
  • GF Value™: HK$1.82 vs. price of HK$2.31 (26.9% above fair value)
  • GF Score™: 78/100 with 2 warning signs

No single metric tells the full story. See the HKSE:08049 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Jilin Province Huinan Changlong Bio-pharmacy Co Business Description

Other Exchanges JIL:Germany
Address 625 & 639 Nathan Road, Room 1101-2, 11th Floor, Office Tower Two, Grand Plaza, Mong kok, Kowloon, Hong Kong, HKG
Jilin Province Huinan Changlong Bio-pharmacy Co Ltd is principally engaged in the manufacture and distribution of Chinese medicines and pharmaceutical products in the PRC under the brand names of Changlong and Qing Tong. The company has only one business segment. It generates revenue from the Sales of Chinese medicines and pharmaceutical products. Geographically, it derives its entire revenue from the PRC.
78GF Score

Get the complete analysis for HKSE:08049

Total Payout Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$2.31
Price
HK$1.82
GF Value